Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1711 to 1725 of 2184 results for guidelines

  1. Gouty arthritis: canakinumab (ESNM23)

    This advice has been updated and replaced by NICE guideline NG219.

    Withdrawn advice

  2. Preventing recurrence of Clostridium difficile infection: bezlotoxumab (ES13)

    This advice has been updated and replaced by NICE guideline NG199.

    Withdrawn advice

  3. Faecal microbiota transplant for recurrent or refractory Clostridioides difficile infection (MIB247)

    This advice has been updated and replaced by NICE guideline NG199.

    Withdrawn advice

  4. Liraglutide for the treatment of type 2 diabetes mellitus (TA203)

    This guidance has been updated and replaced by NICE guideline NG28.

    Withdrawn guidance

  5. Endovascular stent–grafts for the treatment of abdominal aortic aneurysms (TA167)

    This guidance has been updated and replaced by NICE guideline NG156.

    Withdrawn guidance

  6. Parent-training/education programmes in the management of children with conduct disorders (TA102)

    This guidance has been updated and replaced by NICE guideline CG158.

    Withdrawn guidance

  7. Exenatide prolonged-release suspension for injection in combination with oral antidiabetic therapy for the treatment of type 2 diabetes (TA248)

    This guidance has been updated and replaced by NICE guideline NG28.

    Withdrawn guidance

  8. Canakinumab for treating gouty arthritis attacks and reducing the frequency of subsequent attacks (terminated appraisal) (TA281)

    This guidance has been updated and replaced by NICE guideline NG219.

    Withdrawn guidance

  9. Statins for the prevention of cardiovascular events (TA94)

    This guidance has been updated and replaced by NICE guideline CG181.

    Withdrawn guidance

  10. Guidance on the use of photodynamic therapy for age-related macular degeneration (TA68)

    This guidance has been updated and replaced by NICE guideline NG82.

    Withdrawn guidance

  11. Guidance on the use of capecitabine for the treatment of locally advanced or metastatic breast cancer (TA62)

    This appraisal has been updated and replaced by NICE guideline CG81.

    Withdrawn guidance

  12. Bezlotoxumab for preventing recurrent Clostridium difficile infection (terminated appraisal) (TA601)

    This guidance has been updated and replaced by NICE guideline NG199.

    Withdrawn guidance

  13. Looked-after children and young people (PH28)

    This guidance has been updated and replaced by NICE guideline NG205.

    Withdrawn guideline

  14. Sexually transmitted infections and under-18 conceptions: prevention (PH3)

    This guidance has been updated and replaced by NICE guideline NG221.

    Withdrawn guideline

  15. Barrett's oesophagus: ablative therapy (CG106)

    This guidance has been updated and replaced by NICE guideline NG231.

    Withdrawn guideline